News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Increases speed to market for drug developers working on nucleic acid therapeutics
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Subscribe To Our Newsletter & Stay Updated
